Payment overview · 2025
General Payments
$248.13
12 reported records · 4 companies
Healthcare provider profile · identity verified
Mohammad Rezvani, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1487976668
Verified facts
What the public records show
CMS Open Payments records show Mohammad Rezvani, M.D. received $248.13 in general payments during 2025 across 12 reported records.
Kowa Pharmaceuticals America, Inc. accounted for 65.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $161.78 | 65.2% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $32.20 | 13.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.21 | 11.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.94 | 10.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.13 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $161.78 | 9 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $32.20 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
101 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 152 |
| Metformin Hcl | Metformin Hcl | 280 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 72 |
| Gabapentin | Gabapentin | 222 | 61 |
| Losartan Potassium | Losartan Potassium | 200 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 197 | 44 |
| Eliquis | Apixaban | 184 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 45 |
| Furosemide | Furosemide | 139 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 134 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 36 |
| Lisinopril | Lisinopril | 116 | 33 |
| Risperidone | Risperidone | 114 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 33 |
| Omeprazole | Omeprazole | 108 | 34 |
| Jardiance | Empagliflozin | 101 | 26 |
| Trazodone Hcl | Trazodone Hcl | 88 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 28 |
| Carvedilol | Carvedilol | 81 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | suppressed |
| Famotidine | Famotidine | 79 | 24 |
| Divalproex Sodium | Divalproex Sodium | 75 | 13 |
| Levetiracetam | Levetiracetam | 73 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 18 |
| Alendronate Sodium | Alendronate Sodium | 69 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 18 |
| Potassium Chloride | Potassium Chloride | 65 | 15 |
| Simvastatin | Simvastatin | 65 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 14 |
| Mirtazapine | Mirtazapine | 56 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 12 |
| Ibuprofen | Ibuprofen | 54 | 23 |
| Januvia | Sitagliptin Phosphate | 54 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 17 |
| Tradjenta | Linagliptin | 54 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 53 | 15 |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Celecoxib | Celecoxib | 49 | 21 |
| Olanzapine | Olanzapine | 49 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 49 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 18 |
| Montelukast Sodium | Montelukast Sodium | 43 | 13 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Atenolol | Atenolol | 41 | 15 |
| Bethanechol Chloride | Bethanechol Chloride | 39 | suppressed |
| Finasteride | Finasteride | 39 | 12 |
| Spironolactone | Spironolactone | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | 11 |
| Rytary | Carbidopa/Levodopa | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | 16 |
| Lactulose | Lactulose | 34 | 12 |
| Allopurinol | Allopurinol | 33 | 11 |
| Alprazolam | Alprazolam | 33 | 11 |
| Latanoprost | Latanoprost | 33 | suppressed |
| Azithromycin | Azithromycin | 31 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 11 |
| Linzess | Linaclotide | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 15 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 18 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 20 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 11 |
| Ramipril | Ramipril | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 11 |
| Xifaxan | Rifaximin | 20 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 19 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Pimecrolimus | Pimecrolimus | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.13 · 12 records | Kowa Pharmaceuticals America, Inc. | KISUNLA, QULIPTA, UBRELVY, UZEDY, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error